Maze Therapeutics vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Precision Medicine — Renal, Cardiovascular & Metabolic Diseases
Maze Therapeutics is a clinical-stage precision medicine company using human genetics to develop small-molecule drugs for chronic kidney disease and obesity; lead programs MZE829 and MZE782 in Phase 1/2;
About
Maze Therapeutics is a clinical-stage biopharmaceutical company founded in 2019 by Charles Homcy and headquartered in South San Francisco, California, that uses human genetics as its primary drug discovery engine. The company's approach begins with population-scale genetic data to identify individuals who are naturally protected from diseases like chronic kidney disease (CKD), obesity, and cardiovascular disorders — then designs small-molecule drugs that mimic the protective genetic effect in the broader patient population. This genetics-first model is designed to increase the probability of clinical success by targeting validated mechanisms with demonstrated human proof of concept before any clinical trial begins.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.